Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024) - Report - MDSpire

Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024)

  • By

  • Weisong Zhang

  • Guangchen Liu

  • Xue Qu

  • Delong Cong

  • Yangyang Liu

  • May 22, 2026

  • 0 min

Share

Clinical Report: Trends and Developments in Metabolic Syndrome and MAFLD Research

Overview

{'time_frame': 'Specify if the study includes data up to 2024 or only up to 2023.'}

Background

Metabolic syndrome (MetS) is a cluster of conditions that significantly increases the risk of type 2 diabetes and cardiovascular diseases, affecting approximately one-quarter of the global population. The association between MetS and non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated fatty liver disease (MAFLD), underscores the importance of understanding these interrelated conditions for effective diagnosis and management.

Data Highlights

{'table_title': 'Consider a more descriptive title for the table.'}

Key Findings

{'supporting_data': 'Add specific data or references for keyword trends and influential contributors.'}

Clinical Implications

{'examples': 'Provide examples of how findings can be implemented in clinical practice.'}

Conclusion

{'future_directions': 'Emphasize the importance of ongoing research and potential future directions.'}

Related Resources & Content

  1. Journal of Gastroenterology, 2026 -- Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD)
  2. Frontiers in Medicine, 2026 -- The role of mitochondrial dynamics in metabolic dysfunction–associated steatotic liver disease
  3. Archives of Toxicology, 2026 -- Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver–bone model
  4. Frontiers in Pediatrics, 2026 -- Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications
  5. Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease - ScienceDirect
  6. Drug Trials Snapshots: REZDIFFRA | FDA
  7. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
  8. Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease - ScienceDirect
  9. Drug Trials Snapshots: REZDIFFRA | FDA
  10. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine

Original Source(s)

Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024)

  • by Weisong Zhang, Guangchen Liu, Xue Qu, Delong Cong, Yangyang Liu

  • May 22, 2026

Related Content

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026

STAT investigates the epidemic killing 178,000 Americans a year

Association between red cell distribution width and HBV viral load and liver function parameters in patients with chronic hepatitis B: a real-world data study